Navigation Links
Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
Date:10/22/2007

rogression of structural damage and improving physical function in patients with psoriatic arthritis. HUMIRA can be used alone or in combination with methotrexate or other disease-modifying anti- rheumatic drugs (DMARDs). HUMIRA is also approved for reducing signs and symptoms in patients with active ankylosing spondylitis.

Earlier this year, HUMIRA was approved for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and reducing the signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.

Important Safety Information

Serious infections, sepsis, tuberculosis (TB) and opportunistic infections, including fatalities, have been reported with the use of TNF- blocking agents, including HUMIRA. Many of these serious infections have occurred in patients also taking other immunosuppressive agents that in addition to their underlying disease could predispose them to infections. Infections have also been reported in patients receiving HUMIRA alone. Treatment with HUMIRA should not be initiated in patients with active infections. TNF-blocking agents, including HUMIRA, have been associated with reactivation of hepatitis B (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating Humira. The combination of HUMIRA and anakinra is not recommended and patients using HUMIRA should not receive live vaccines.

More cases of malignancies have been observed among patients receiving TNF blockers, including HUMIRA, compared to control patients in clinical trials. These malignancies, other than
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
4. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
5. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
6. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
7. New Advances in Gastric Diagnostics: Smaller is Better
8. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
9. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
10. Non-Invasive Diagnostic Tests for Celiac Disease
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... healthcare supply chain experts will showcase best practices for ... hospitals—supply chain costs—at the GHX booth during the AHRMM11 ... taking on a more strategic role in hospitals across ... also to provide data visibility that can dramatically impact ...
... 5, 2011 Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a ... and contract research and manufacturing services to customers located ... first quarter of fiscal year (FY) 2012, ended June ... report that in the first quarter of the new ...
Cached Medicine Technology:GHX Spotlights Supply Chain Role in Reducing Costs and Improving Patient Care at the AHRMM11 Annual Conference 2GHX Spotlights Supply Chain Role in Reducing Costs and Improving Patient Care at the AHRMM11 Annual Conference 3Neuland Labs Reports First Quarter Fiscal Year 2012 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2012 Financial Results 3
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... , MORRISTOWN, N.J., July 27 ... ), a leader in generic and specialty branded pharmaceuticals, announced that ... Officer, has taken a leave of absence from the Company for ... Watson, announced that R. Todd Joyce, Vice President, Corporate Controller and ...
... , , NEW YORK, July ... company developing a minimally invasive drug delivery platform for the regional treatment of ... In addition, the Company reported its financial results for the second quarter ended ... , , Screened 40 Additional Patients ...
... , SWIFTWATER, Pa., July 27 Sanofi ... SNY ), announced today that it has shipped the ... Fluzone vaccine is indicated for active immunization in people 6 months ... subtypes A and type B contained in the seasonal influenza vaccine. ...
... , , ... California Cardiothoracic Surgery Center specializes in cardiothoracic surgery including ... seem like serious symptoms. In fact, most people brush off these ... symptoms can be indications of the need for mitral ...
... , , , , ... AMGN ) reported adjusted earnings per share (EPS) of $1.29 for the ... second quarter of 2008. Adjusted net income increased 6 percent to $1,311 million ... of 2008. , , Total revenue decreased 1 percent during the ...
... , , WASHINGTON, July ... Action, the legislative lobbying arm of Family Research Council, will ... President Obama,s proposed government takeover of the health care system. ... Congressional leaders to discuss the moral, ethical, and financial dangers ...
Cached Medicine News:Health News:Watson CFO Mark W. Durand to Take Leave of Absence 2Health News:Delcath Systems Provides Update on Progress 2Health News:Delcath Systems Provides Update on Progress 3Health News:Delcath Systems Provides Update on Progress 4Health News:Delcath Systems Provides Update on Progress 5Health News:Delcath Systems Provides Update on Progress 6Health News:Delcath Systems Provides Update on Progress 7Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 2Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 3Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 4Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 5Health News:Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza 6Health News:Southern California Surgical Center (heart411.com) Specializes in Mitral Valve Replacement 2Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 2Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 3Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 4Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 5Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 6Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 7Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 8Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 9Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 10Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 11Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 12Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 13Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 14Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 15Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 16Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 17Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 18Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 19Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 20Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 21Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 22Health News:Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29 23
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features: Eppendorf "pipette/tip" ...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 100-1,000 microliter range....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,409-7) or contact custom...
Medicine Products: